Investor relations.
Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer, GMP-licensed by Health Canada, producing MDMA capsules and natural psilocybin extract for regulated treatment programs. This page provides the official stock, filings, and disclosure channels for investors.
| Product | Australia TGA APS | Canada Health Canada SAP | United States FDA pathway | European Union National schemes |
|---|---|---|---|---|
Natural Psilocybin Extract 4-PO-DMT · Capsule | Shipping Since 2024; routine exports | Supplying Special Access Program | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
MDMA 60 mg MDMA HCl · Capsule | Shipping Active under APS | Supplying SAP + clinical trials | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
MDMA 40 mg MDMA HCl · Capsule | Shipping Active under APS | Supplying SAP + clinical trials | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
Ibogaine Initiative · 2026 | Evaluating Assessing APS framework | Planned GMP scale-up 2026 | Planned Post-EO / IND clearance (Apr 2026) | Evaluating Monitoring national access |
Status reflects current Company operations. Optimi supplies product into regulated access pathways rather than conducting clinical trials as a drug developer. Shipping = routine commercial exports; Supplying = active supply into research programs or special-access pathways; Planned = infrastructure in place, awaiting regulatory access; Evaluating = tracking the jurisdiction.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Optimi intends to complete a portion of its previously announced common share offering in Canada pursuant to the Listed Issuer Financing Exemption under National Instrument 45-106, alongside its US offering led by Joseph Gunnar & Co.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework